186651-05-8

Basic information

• Product Name: 4-(2-OXO-PIPERIDIN-1-YL)-BENZONITRILE
• Synonyms: 4-(2-OXO-PIPERIDIN-1-YL)-BENZONITRILE
• CAS NO: 186651-05-8
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.23648
• Mol File: 186651-05-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-OXO-PIPERIDIN-1-YL)-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-OXO-PIPERIDIN-1-YL)-BENZONITRILE(186651-05-8)
• EPA Substance Registry System: 4-(2-OXO-PIPERIDIN-1-YL)-BENZONITRILE(186651-05-8)

Safety Data

• Hazardous Substances Data: 186651-05-8(Hazardous Substances Data)

Upstream product

• 675-20-7 piperidin-2-one 
• 3058-39-7 4-iodobenzonitrile 
• 623-00-7 4-bromobenzenecarbonitrile 
• 873-74-5 4-Aminobenzonitrile 
• 1575-61-7 5-Chlorovaleroyl chloride 

Relevant articles and documents

SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI

Substituted oxadiazoles for combating phytopathogenic fungi The present invention relates the use of the compounds of the formula I, or the N-oxides, or the agriculturally acceptable salts thereof for combating phytopathogenic harmful fungi. Further, the present invention relates to novel compounds, to mixtures comprising at least one such compound of the formula I and at least one further pesticidally active substance selected from the group consisting of herbicides, safeners, fungicides, insecticides, and plant growth regulators; and to agrochemical compositions comprising at least one such compound of the formula I and to agrochemical compositions further comprising seeds.

Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element

Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazole/tetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50(FXa) value of 0.15?μM and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor.